System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Robin Michelet is an expert in Pharmacy at Freie Universität Berlin (Germany). Robin Michelet has authored 88 publications, the most recent in 2025, and is an investigator in 4 clinical trials. SLR score: 294 (community average: 125). How the SLR is computed.

LeadR Profile

Robin Michelet Freie Universität Berlin Germany
294 ScienceLeadR Reputation 294

Unlock

Register Login
Network Map

Pharmacy

Subspecialties: Oncology - Pulmonology - Pediatrics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2014 - 2026
Source: PubMed

Freie Universität Berlin

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 88

Citations

Citations: 859 1st author: 11 Last author: 5 Unique author: 0

Main journals

Clin Pharmacokinet 9
Pharmaceutics 7
Clin Pharmacol Ther 4
Eur J Pharm Sci 4
Antibiotics (Basel) 3

Best Journals

Ann Oncol 1
Intensive Care Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Physiologically Motivated Sequential Population Modeling of Albumin Trends and Vedolizumab Pharmacokinetics for Pregnancy Dosing Regimen Optimization.
PMID 41392610 — pregnancy, plasma volume, pregnancy outcome, drug therapy, pharmacology, work, plasma, pharmacokinetics		Clin Pharmacol Ther20250
TLD-1, a Novel Liposomal Doxorubicin, in Patients with Solid Tumors: Comparative Pharmacokinetics and Final Results of a Multicenter Phase 1 Study (SAKK 65/16).
PMID 41252081 — breast neoplasms, doxorubicin, neoplasms, pharmacology, breast, pharmacokinetics		Clin Pharmacokinet20250
The β-lactamase inhibitor concentration-dependent minimum inhibitory concentration (MICcBLI) as methodology to assess the pharmacokinetic/pharmacodynamic relationship of piperacillin/tazobactam for dosing optimization.
PMID 41230609 — piperacillin, tazobactam drug combination, piperacillin, tazobactam, drug therapy, lactams		J Antimicrob Chemother20250
Model-informed identification of optimised dosing strategies for meropenem in critically ill patients receiving SLEDD: an observational study.
PMID 40279026 — nomograms, critical illness, meropenem, therapeutics, infections		Infection20250
Author's Reply to Helsby and Hannam: 'Understanding Voriconazole Metabolism: A Middle-Out Physiologically-Based Pharmacokinetic Modelling Framework Integrating In Vitro and Clinical Insights'.
PMID 40750725 — voriconazole, pharmacology		Clin Pharmacokinet20250

Clinical Studies 4

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 4 2
N/A 1
Phase 1 1

By status:

Completed 3
Terminated 1

By type:

Interventional 3
Observational 1

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 1
multicentricup10 0

Main Topics

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS